Risedronic acid

Identification

Summary

Risedronic acid is a bisphosphonate used to treat osteoporosis and Paget's disease.

Brand Names
Actonel, Atelvia
Generic Name
Risedronic acid
DrugBank Accession Number
DB00884
Background

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's diseaseLabel1,2. It functions by preventing resorption of boneLabel1.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 283.1123
Monoisotopic: 283.001074735
Chemical Formula
C7H11NO7P2
Synonyms
  • Acide risédroniqe
  • Acido risedronico
  • Acidum risedronicum
  • Risedronate
  • Risedronic acid
  • Risedronsäure
External IDs
  • NE-58095

Pharmacology

Indication

Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosisLabel.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofHypercalcemia of malignancy••• •••••
Used in combination to preventOsteoporosisRegimen in combination with: Calcium (DB01373), Cholecalciferol (DB00169)••••••••••••••••••••••••••
Used in combination to manageOsteoporosisRegimen in combination with: Calcium (DB01373), Cholecalciferol (DB00169)••••••••••••••••••••••••••
Treatment ofOsteoporosis•••••••••••••••••••••••••••
Treatment ofOsteoporosis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclastsLabel.

Mechanism of action

Risedronatic acid binds to bone hydroxyapatiteLabel. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis1. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase1. Inhibition of osteoclasts results in decreased bone resorption1.

TargetActionsOrganism
AHydroxylapatite
antagonist
Humans
AFarnesyl pyrophosphate synthase
inhibitor
Humans
Absorption

Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosingLabel. Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30%Label.

Volume of distribution

13.8 L/kgLabel.

Protein binding

~24%Label.

Metabolism

Risedronic acid is not likely not metabolized before eliminationLabel. The P-C-P group of bisphosphonates is resistant to chemical and enzymatic hydrolysis preventing metabolism of the molecule1.

Route of elimination

Risedronate is excreted by the kidneys and the unabsorbed dose is eliminated in the fecesLabel.

Half-life

The initial half life of risedronic acid is approximately 1.5 hours3, with a terminal half life of 561 hoursLabel.

Clearance

Mean renal clearance was 52mL/min and mean total clearance was 73mL/minLabel.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsiaLabel. Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitisLabel.

Patients experiencing an overdose may experience a decrease in serum calcium and phosphorusLabel. Patients can be given milk or antacids to bind the drug and reduce its absorptionLabel. In more severe cases, patients may require gastric lavage and intravenous calciumLabel. A lethal dose in rats is equivalent to 320 to 620 times the human dose based on surface areaLabel.

Pathways
PathwayCategory
Risedronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Risedronic acid.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Risedronic acid.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Risedronic acid.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox.
AcyclovirThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Risedronic acid.
Food Interactions
  • Administer vitamin supplements. Patients may require supplemental vitamin D.
  • Avoid multivalent ions. Calcium, antacids, and divalent ions may interfere with the absorption of this medication.
  • Take on an empty stomach.
  • Take with a full glass of water.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Risedronate sodiumOFG5EXG60L115436-72-1DRFDPXKCEWYIAW-UHFFFAOYSA-M
Risedronate sodium hemi-pentahydrateHU2YAQ274O329003-65-8HYFDYHPNTXOPPO-UHFFFAOYSA-L
Risedronate sodium monohydrateF67L43UT5C353228-19-0KLQNARDFMJRXSF-UHFFFAOYSA-M
Product Images
International/Other Brands
Benet (Takeda ) / Ridron
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ActonelTablet, film coated75 mg/1OralWarner Chilcott2007-04-162010-03-31US flag
ActonelTablet, film coated35 mg/1OralPhysicians Total Care, Inc.2002-09-16Not applicableUS flag
ActonelTablet30 mgOralAllergan Pharma Co.1999-09-072019-01-04Canada flag
ActonelTablet, film coated30 mg/1OralWarner Chilcott1998-03-27Not applicableUS flag
ActonelTablet150 mgOralAbbvie2008-12-01Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Aa-risedronate DrTablet, delayed release35 mgOralAa Pharma Inc2021-05-18Not applicableCanada flag
Apo-risedronateTablet150 mgOralApotex Corporation2012-05-17Not applicableCanada flag
Apo-risedronateTablet35 mgOralApotex Corporation2010-11-10Not applicableCanada flag
Auro-risedronateTablet35 mgOralAuro Pharma Inc2013-07-08Not applicableCanada flag
Auro-risedronateTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ActonelRisedronate sodium hemi-pentahydrate (129 mg/1) + Risedronate sodium monohydrate (21 mg/1)Tablet, film coatedOralAllergan, Inc.2008-04-22Not applicableUS flag
ActonelRisedronate sodium hemi-pentahydrate (64.5 mg/1) + Risedronate sodium monohydrate (10.5 mg/1)Tablet, film coatedOralAllergan, Inc.2007-04-162010-03-31US flag
ActonelRisedronate sodium hemi-pentahydrate (25.8 mg/1) + Risedronate sodium monohydrate (4.2 mg/1)Tablet, film coatedOralAllergan, Inc.1998-03-272020-02-28US flag
ActonelRisedronate sodium hemi-pentahydrate (4.3 mg/1) + Risedronate sodium monohydrate (0.7 mg/1)Tablet, film coatedOralAllergan, Inc.2000-04-142020-07-28US flag
ActonelRisedronate sodium hemi-pentahydrate (129 mg/1) + Risedronate sodium monohydrate (21 mg/1)Tablet, film coatedOralAllergan, Inc.2008-04-22Not applicableUS flag

Categories

ATC Codes
M05BB07 — Risedronic acid and colecalciferolM05BB02 — Risedronic acid and calcium, sequentialM05BB04 — Risedronic acid, calcium and colecalciferol, sequentialM05BA07 — Risedronic acid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Pyridines and derivatives / Organic phosphonic acids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic heteromonocyclic compound / Azacycle / Bisphosphonate / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridines (CHEBI:8869)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
KM2Z91756Z
CAS number
105462-24-6
InChI Key
IIDJRNMFWXDHID-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
IUPAC Name
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
SMILES
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O

References

Synthesis Reference

Srinivasa Rao V.N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala, "Process for the preparation of risedronate sodium hemi-pentahydrate." U.S. Patent US20070173484, issued July 26, 2007.

US20070173484
General References
  1. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [Article]
  2. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. [Article]
  3. Thompson Micromedex (2004). Usp Vol I Drug Info Health Vol: Volume I (USP DI: v.1 Drug Information for the Health Care Professional) (24th ed., pp. 2475). Thompson PDR. [ISBN:1563634635]
  4. Risedronate Sodium Tablet MSDS [Link]
  5. FDA Approved Drugs: Risedronic Acid Oral Tablets [Link]
  6. FDA Approved Drug Products: Risedronic Acid Extended Release Tablets [Link]
Human Metabolome Database
HMDB0015022
KEGG Drug
D08484
KEGG Compound
C08233
PubChem Compound
5245
PubChem Substance
46507526
ChemSpider
5055
BindingDB
12576
RxNav
55685
ChEBI
8869
ChEMBL
CHEMBL923
ZINC
ZINC000001531009
Therapeutic Targets Database
DAP000658
PharmGKB
PA451255
PDBe Ligand
RIS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Risedronic_acid
PDB Entries
1rqj / 1yhl / 1yq7 / 1yv5 / 2o1o / 2qis / 4kpd / 4kqs / 4n9u / 4ng6
show 9 more
FDA label
Download (229 KB)
MSDS
Download (69.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableCrohn's Disease (CD) / Decreased bone mineral density1
4CompletedPreventionBone Fractures / Bone Loss / Epilepsy / Osteoporosis1
4CompletedPreventionBone Loss / Breast Cancer / Osteoporosis1
4CompletedPreventionCystic Fibrosis (CF) / Duchenne Muscular Dystrophy (DMD) / Osteoporosis1
4CompletedPreventionPostmenopausal Osteoporosis1

Pharmacoeconomics

Manufacturers
  • Warner chilcott co llc
  • Teva pharmaceuticals usa
  • Procter & Gamble
Packagers
  • Diversified Healthcare Services Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Norwich Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Procter & Gamble
  • Resource Optimization and Innovation LLC
  • Stat Rx Usa
  • Warner Chilcott Co. Inc.
  • WC Pharmaceuticals
Dosage Forms
FormRouteStrength
Tablet, film coatedOral35 mg
Tablet, effervescent
TabletOral75 mg
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral35 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral75 mg/1
Tablet, film coatedOral30 MG
Tablet, film coatedOral75 MG
Tablet, delayed releaseOral35 mg
Tablet, coatedOral150 mg
Tablet, film coatedOral150 mg
Granule, effervescent; kit; tabletOral
Tablet, film coatedOral5 mg
KitOral
TabletOral35.000 mg
TabletOral150 mg
Tablet, delayed releaseOral
Tablet, effervescent150 mg
Tablet, effervescent75 mg
Tablet, coatedOral
TabletOral
TabletOral35.00 mg
Tablet, film coatedOral
Tablet, delayed releaseOral35 mg/1
Tablet, film coatedOral
PowderNot applicable1 kg/1kg
TabletOral
Tablet, effervescentOral
TabletOral5.000 mg
TabletOral30 mg
TabletOral35 mg
TabletOral5 mg
Kit; tabletOral
Tablet, coatedOral35 mg
Prices
Unit descriptionCostUnit
Actonel 150 mg tablet125.1USD tablet
Actonel 4 35 mg tablet Disp Pack119.43USD disp
Actonel 75 mg tablet54.83USD tablet
Actonel 30 mg tablet29.32USD tablet
Actonel 35 mg tablet28.75USD tablet
Actonel 5 mg tablet4.13USD tablet
Actonel with calcium tablet3.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6096342No2000-08-012011-11-22US flag
CA2294595No2001-08-212018-07-17Canada flag
CA2399976No2007-03-272021-02-01Canada flag
US7192938Yes2007-03-202023-11-06US flag
US7718634Yes2010-05-182023-11-06US flag
US6165513Yes2000-12-262018-12-10US flag
US5994329Yes1999-11-302019-01-17US flag
US6015801Yes2000-01-182019-01-17US flag
US6432932Yes2002-08-132019-01-17US flag
US6465443Yes2002-10-152019-02-14US flag
US7645459No2010-01-122028-01-09US flag
US7645460No2010-01-122028-01-09US flag
US8246989No2012-08-212026-01-16US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)252-262https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/RISEDRONATE%20SODIUM%20TABLETS%20MSDS_0.pdf
boiling point (°C)692.3https://www.greenstonellc.com/sites/default/files/pdfs/MSDS/RISEDRONATE%20SODIUM%20TABLETS%20MSDS_0.pdf
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP-0.75ALOGPS
logP-3.3Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.68Chemaxon
pKa (Strongest Basic)4.91Chemaxon
Physiological Charge-3Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area148.18 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity57.12 m3·mol-1Chemaxon
Polarizability21.91 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9357
Blood Brain Barrier+0.9172
Caco-2 permeable-0.6795
P-glycoprotein substrateNon-substrate0.6846
P-glycoprotein inhibitor INon-inhibitor0.9582
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9542
CYP450 2C9 substrateNon-substrate0.8452
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateNon-inhibitor0.8778
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.9062
CYP450 2C19 inhibitorNon-inhibitor0.8777
CYP450 3A4 inhibitorNon-inhibitor0.9068
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.989
Ames testNon AMES toxic0.7663
CarcinogenicityNon-carcinogens0.8386
BiodegradationNot ready biodegradable0.5058
Rat acute toxicity2.1053 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9095
hERG inhibition (predictor II)Non-inhibitor0.9303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001l-9030000000-834cccb13596d4a6e4c2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ue9-0490000000-57ddb91ff8ccb149a8a2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0790000000-c2a233ca5a42b3cdd925
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-f4a556d28a85f9424b04
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fr-9030000000-dea17b00a079a831b2c2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kf-9100000000-a8daf608efb1da969f9c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fr-9010000000-02449ab92bded9025cc5
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-161.6330857
predicted
DarkChem Lite v0.1.0
[M-H]-144.6663
predicted
DeepCCS 1.0 (2019)
[M+H]+160.9833857
predicted
DarkChem Lite v0.1.0
[M+H]+147.06187
predicted
DeepCCS 1.0 (2019)
[M+Na]+160.4181857
predicted
DarkChem Lite v0.1.0
[M+Na]+153.03542
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Small molecule
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [Article]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [Article]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  3. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58. [Article]
  4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [Article]
  5. Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64. [Article]
  6. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. doi: 10.1186/ar3122. Epub 2010 Aug 25. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48